Hertuzumab has been conjugated with auristatin E via a protease cleavable linker [74], showing a promising clinical effect in patients diagnosed with HER-2-positive breast cancer and previously treated with trastuzumab, with an overall response rate above 70% [75]. This evidence concerns the gene ERBB2 and breast carcinoma.